Quest Diagnostics Inc. (DGX) Valuation

Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic path...

Quest Diagnostics Inc. (DGX) currently trades at a P/E ratio of 26.76 (historical range: 19.56–26.83, median: 21.50), placing it at the 99th percentile — expensive relative to its history, P/S ratio of 2.43 (range: 1.72–2.44, 99th percentile — expensive relative to its history), EV/EBITDA of 80.62 (range: 15.69–80.79, 99th percentile).

Quest Diagnostics Inc. appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.

Historical Valuation Metrics

MetricCurrentMinMedianMaxPercentileAssessment
P/E Ratio26.7619.5621.5026.8399thexpensive relative to its history
P/S Ratio2.431.721.932.4499thexpensive relative to its history
EV/EBITDA80.6215.6930.1880.7999thexpensive relative to its history
FCF Yield0.010.010.030.070thexpensive relative to its history
Current Price: $240.30
Market Cap: $26.5B
Sector: Healthcare